© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
January 08, 2021
Current gaps in the prevention/treatment of C. difficile infections, as highlighted by leading healthcare professionals.
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.
A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.
Important factors to consider when selecting an appropriate therapy to treat C. difficile.
Implications regarding how to properly treat patients with C. difficile infections based on data that has emerged since clinical practice guidelines were last updated.
Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.
A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.
Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.
Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.